Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
{"title":"Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017–2023","authors":"Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed","doi":"10.1111/apt.18501","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017–2023), we found the age-adjusted prevalence of lean SLD to be 12.8%. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively.</p>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 5","pages":"891-894"},"PeriodicalIF":6.7000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18501","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017–2023), we found the age-adjusted prevalence of lean SLD to be 12.8%. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively.
我们的研究调查了瘦肉成年人中瘦肉脂肪变性肝病（SLD）及其亚类别的患病率，包括代谢功能障碍相关脂肪变性肝病（MASLD）、代谢功能障碍相关和酒精相关SLD （MetALD）以及酒精相关肝病（ALD）。分析来自2017-2023年全国健康与营养调查（National Health and Nutrition Examination Survey）的2965名瘦肉成年人（≥18岁）的数据，我们发现瘦肉SLD的年龄调整患病率为12.8%。具体来说，瘦型MASLD的患病率为9.3%，MetALD的患病率为1.3%，ALD的患病率为1.0%。值得注意的是，在MASLD组中，显著纤维化、晚期纤维化和肝硬化的发生率分别为5.6%、2.4%和2.0%。
期刊介绍：
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
